Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Burkitt Lymphoma 1

Interventions

venetoclax 108Azacitidine 92Cytarabine 77Specimen Handling 52fludarabine 47Biopsy 38Daunorubicin 31Cyclophosphamide 31Injections 29Decitabine 29Idarubicin 27fludarabine phosphate 25Granulocyte Colony-Stimulating Factor 22Busulfan 22Whole-Body Irradiation 20Mycophenolic Acid 20Tacrolimus 18decitabine and cedazuridine drug combination 17Melphalan 17CPX-351 17Stem Cell Transplantation 16gilteritinib 14Mitoxantrone 14ivosidenib 13Filgrastim 13Peripheral Blood Stem Cell Transplantation 12Cladribine 12Magnetic Resonance Spectroscopy 11Etoposide 11Cyclosporine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Leyk × 90 days × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡